We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GlaxoSmithKline (GSK) selectively presented efficacy data and omitted important risk information in a letter to physicians announcing the launch of Tykerb, a kinase inhibitor indicated for the second-line treatment of HER2-positive metastatic breast cancer, according to the FDA.